Shots:
- Chime Biologics and Daewoong Pharmaceutical signed a strategic partnership to develop and manufacture a biosimilar version of Dupixent
- Chime Biologics will support Daewoong’s global biosimilar ambitions with its end-to-end development expertise, AI platform, and China’s bioprocess supply chain ecosystem
- Dupilumab (Dupixent) is a mAb that blocks IL-4 and IL-13 signaling to treat Type 2 inflammation
Ref: Chime Biologics | Image: Chime Biologics and Daewoong Pharmaceutical | Press Release
Related News: Celltrion Seeks Canadian Approval for CT-P55 (Biosimilar, Cosentyx)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
